Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir

Molnupiravir

 

Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir

U.S FDA advisory panel narrowly endorses Molnupiravir, for Mild to Moderate COVID-19 in High Risk patients, despite reduced efficacy and safety questions .

A Food and Drug Administration advisory panel on Tuesday narrowly endorsed the use of Merck and Ridgeback’s at-home Covid treatment pill, despite questions about the drug’s safety, effectiveness and whether it would help the virus mutate into even more dangerous variants.

Some of the most important points that have been discussed about are:

  • The FDA’s Antimicrobial Drugs panel of advisory voted 13 to 10 to recommend emergency authorization of molnupiravir.
  • Most committee members said it was a difficult vote, with unanswered questions about the drug’s potential impact, however unlikely, on driving virus evolution and safety .
  • Molnupiravir is an antiviral drug designed to treat adults with mild to moderate symptoms of Covid-19 who are exposed to high risk of severe disease, one of the distinguishing points of molnupiravir is its oral administration of use.
  • Still the drug needs final authorization from the FDA and CDC before it’s available to the public on an emergency basis.

product related:

Molnupiravir

You can find out more regarding this news on following links:

https://www.fda.gov/

https://www.merck.com/

Enter your email to receive the catalog

Download
close-link